These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33170724)

  • 1. Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
    Alhudaithi SS; Almuqbil RM; Zhang H; Bielski ER; Du W; Sunbul FS; Bos PD; da Rocha SRP
    Mol Pharm; 2020 Dec; 17(12):4691-4703. PubMed ID: 33170724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model.
    Zhang H; Almuqbil RM; Alhudaithi SS; Sunbul FS; da Rocha SRP
    Int J Pharm; 2021 Apr; 598():120350. PubMed ID: 33545279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
    Cuccarese MF; Dubach JM; Pfirschke C; Engblom C; Garris C; Miller MA; Pittet MJ; Weissleder R
    Nat Commun; 2017 Feb; 8():14293. PubMed ID: 28176769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1.
    Shih CT; Shiau CW; Chen YL; Chen LJ; Chao TI; Wang CY; Huang CY; Hung MH; Chen KF
    Cancer Lett; 2021 Feb; 498():142-151. PubMed ID: 33232786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic Immunity.
    Barnwal A; Gaur V; Sengupta A; Tyagi W; Das S; Bhattacharyya J
    ACS Biomater Sci Eng; 2023 Nov; 9(11):6409-6424. PubMed ID: 37870457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
    Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
    Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
    Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
    J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization.
    Leonard F; Curtis LT; Hamed AR; Zhang C; Chau E; Sieving D; Godin B; Frieboes HB
    Cancer Immunol Immunother; 2020 May; 69(5):731-744. PubMed ID: 32036448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
    Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.
    Yan D; Kowal J; Akkari L; Schuhmacher AJ; Huse JT; West BL; Joyce JA
    Oncogene; 2017 Oct; 36(43):6049-6058. PubMed ID: 28759044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.
    Pass HI; Lavilla C; Canino C; Goparaju C; Preiss J; Noreen S; Blandino G; Cioce M
    Oncotarget; 2016 Aug; 7(35):56408-56421. PubMed ID: 27486763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts.
    Shimizu D; Yuge R; Kitadai Y; Ariyoshi M; Miyamoto R; Hiyama Y; Takigawa H; Urabe Y; Oka S
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment.
    Jiang M; He K; Qiu T; Sun J; Liu Q; Zhang X; Zheng H
    Int J Pharm; 2020 May; 581():119239. PubMed ID: 32194211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    DeNardo DG; Brennan DJ; Rexhepaj E; Ruffell B; Shiao SL; Madden SF; Gallagher WM; Wadhwani N; Keil SD; Junaid SA; Rugo HS; Hwang ES; Jirström K; West BL; Coussens LM
    Cancer Discov; 2011 Jun; 1(1):54-67. PubMed ID: 22039576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
    Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
    Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
    [No Abstract]   [Full Text] [Related]  

  • 19. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
    Guerriero JL; Sotayo A; Ponichtera HE; Castrillon JA; Pourzia AL; Schad S; Johnson SF; Carrasco RD; Lazo S; Bronson RT; Davis SP; Lobera M; Nolan MA; Letai A
    Nature; 2017 Mar; 543(7645):428-432. PubMed ID: 28273064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.